Skip to main content

Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Size, Share, Report, Analysis, Trends & Forecast to 2026

According to Stratistics MRC, the Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market is accounted for $1.91 billion in 2017 and is expected to reach $4.96 billion by 2026 growing at a CAGR of 11.2% during the forecast period.

Gaithersburg, Maryland, United States - July 9, 2019 /MarketersMedia/

Factors such as increasing special drug designation, proven efficacy of EGFR inhibitors and the growing prevalence of cancer indications are fuelling the market growth. However, prevent cell growth would be hindered by all participants receiving EGFR.

Request for sample here: https://www.strategymrc.com/report/epidermal-growth-factor-receptor-egfr-inhibitors-market/request-sample

The Epidermal growth factor receptor (EGFR, also known as ErbB-1 or HER-1) inhibitors are medicines that bind to certain parts of the EGFR and slow down or stop cell growth. EGFR is a protein that is found on the surface of some cells that causes cells to divide when epidermal growth factor binds to it. EGFR is found at abnormally high levels in cancer cells, and EGFR activation appears to be important in tumour growth and progression. Some types of cancers show mutations in their EGFRs, which may cause unregulated cell division through continual or abnormal activation of the EGFR. EGFR inhibitors may be used in the treatment of cancers that are caused by EGFR up-regulation, such as non-small-cell lung cancer, pancreatic cancer, breast cancer, and colon cancer.

Based on indication, the market is segmented into lung cancer, colorectal cancer, breast cancer, and others. Lung cancer is the leading cause of cancer-related death in both men and women in the United States, and the median 5-year survival rate for lung cancer is 5% worldwide.1 Lung cancer is divided into 2 major categories based on histological features: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), which constitute 15% and 85% of lung cancer cases, respectively. By Geography, North American region led the epidermal growth factor receptor inhibitors market. The growth of the epidermal growth factor receptor inhibitors market in North America can be attributed to factors such as the increasing prevalence of the various types of major cancer indications, heavy sales of approved therapeutics, and the presence of various patient programs from both the vendors and the governments in the region.

Access the complete report at: https://www.strategymrc.com/report/epidermal-growth-factor-receptor-egfr-inhibitors-market

Some of the key players profiled in the Epidermal Growth Factor Receptor (EGFR) Inhibitors market include Amgen Inc, Bristol-Myers Squibb, Erbitux, F. Hoffmann-La Roche Ltd, Genentech, Inc, OSI Pharmaceuticals Inc, Tarceva and Vectibix.

Make an inquiry at: https://www.strategymrc.com/report/epidermal-growth-factor-receptor-egfr-inhibitors-market

Indications Covered:
• Breast Cancer
• Colorectal Cancer
• Lung Cancer
• Others Indications

Blocking Drugs Covered:
• Monoclonal Antibodies
• Tyrosine Kinase Inhibitors (TKI)

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o France
o Italy
o UK
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 9 years of all the mentioned segments, sub-segments, and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Follow us on Twitter: https://twitter.com/StratisticsMRC

Follow us on LinkedIn at: https://www.linkedin.com/company/stratistics-market-research-consulting-pvt-ltd?trk=mini-profile

About Stratistics MRC
We offer a wide spectrum of research and consulting services with in-depth knowledge of different industries. We are known for customized research services, consulting services, and Full-Time Equivalent (FTE) services in the research world. We explore market trends and draw our insights with valid assessments and analytical views. We use advanced techniques and tools among the quantitative and qualitative methodologies to identify the market trends.

Our research reports and publications are routed to help our clients to design their business models and enhance their business growth in the competitive market scenario. We have a strong team with hand-picked consultants including project managers, implementers, industry experts, researchers, research evaluators and analysts with years of experience in delivering the complex projects.

Contact Info:
Name: James Lamb
Email: Send Email
Organization: Stratistics Market Research Consulting Pvt Ltd
Phone: +1-301-202-5929
Website: https://www.strategymrc.com

Source URL: https://marketersmedia.com/epidermal-growth-factor-receptor-egfr-inhibitors-market-size-share-report-analysis-trends-forecast-to-2026/88894363

Source: MarketersMedia

Release ID: 88894363

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.